Vincent and Rich discuss avian influenza virus and an antiviral drug against smallpox with Dennis and Yoshi at the ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC.
In this second consecutive all-email episode, the complete TWiV team reads questions and comments from listeners about systemic antiviral responses, wild type poliovirus in Israel, Turkish scientists, viral symbiotes, and much more.
Vincent and Rich recorded this episode before an audience at the 2nd Li Ka Shing Institute of Virology Symposium at the University of Alberta, where they spoke with Dave, Stan, and Lorne about their work on poxvirus vaccines and recombination, an enveloped picornavirus, antivirals against hepatitis B and C viruses, and supporting virology research in Alberta.
Vincent, Rich, and Abbie review a broad spectrum antiviral protein, and selective pressure applied by a failed HIV-1 vaccine.
Vincent, Alan, and Rich discuss growth in culture of newly identified rhinovirus C, vaccinia transmission among wrestlers and martial artists, and results of phase III clinical trial of boceprevir, a new inhibitor of hepatitis C virus replication.
A conversation about careers in virology, systems biology, innate immunity, and antiviral research recorded at the University of Washington in Seattle.
Vincent, Rich, and Ed discuss the transition from academic scientist to government work, the general program of drug and vaccine development in the biodefense world and at BARDA, and career opportunities for scientists in government.
On episode 99 of the podcast This Week in Virology, Vincent tours the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, speaking with exhibitors and visitors, including Professors Derek Smith, Michael Schmidt, Frederick Hayden, and Myra McClure.
Vincent, Rich, Karla, and Marilyn recorded TWiV at the 29th Annual Meeting of the American Society for Virology in Bozeman, where they discussed plant viruses and how they make plants resistant to adverse conditions, and identification of dominant negative drug targets.
Vincent and Michael Gale discuss the origin, pathogenesis, prevention, of hepatitis C virus, and how it evades innate immune responses.